Literature DB >> 1259263

1-alphahydroxycholecalciferol in chronic renal failure. Studies of the effect or oral doses.

M W Davie, T M Chalmers, J O Hunter, B Pelc, E Kodicek.   

Abstract

Four patients with advanced chronic renal failure and osteodystrophy were treated with 1-alphahydroxycholecalciferol, a synthetic vitamin D analogue, in a daily oral dose of 1.5 to 2.0 mug, for periods up to 1 year. They showed increased calcium absorption, positive calcium and phosphorus balances, moderate increases in serum calcium levels, marked reductions in serum alkaline phosphatase levels, a decrease in serum immunoreactive parathyroid hormone levels, and radiologic and histologic improvement in bone disease. One patient with proximal myopathy showed improvement in muscular strength. 1-Alphahydroxycholecalciferol appears to be effective therapy for renal osteodystrophy.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1259263     DOI: 10.7326/0003-4819-84-3-281

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  5 in total

1.  Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.

Authors:  J A Kanis; R G Henderson; G Heynen; J G Ledingham; R G Russell; R Smith; R J Walton
Journal:  Arch Dis Child       Date:  1977-06       Impact factor: 3.791

2.  1alpha-Hydroxycholecalciferol in renal osteodystrophy.

Authors:  A M Pierides; H A Ellis; M K Ward; W Simpson; D N Kerr
Journal:  Calcif Tissue Res       Date:  1977-05

Review 3.  Vitamin D deficient states. Pathophysiology and treatment.

Authors:  M D Jacobs
Journal:  West J Med       Date:  1979-10

4.  Osteomalacic dialysis osteodystrophy: a trial of phosphate-enriched dialysis fluid.

Authors:  T G Feest; M K Ward; H A Ellis; P Aljama; D N Kerr
Journal:  Br Med J       Date:  1978-01-07

Review 5.  Pharmacology and therapeutic use of vitamin D and its analogues.

Authors:  A M Pierides
Journal:  Drugs       Date:  1981-04       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.